Chairman's overview. 
The place of reboxetine in antidepressant therapy

Montgomery SA

Imperial College of Medicine at St Mary's, London, UK.
J Clin Psychiatry 1998; 59 Suppl 14:26-9

ABSTRACT

A comprehensive series of clinical trials have compared the unique selective NRI reboxetine with placebo and with the TCAs imipramine and desipramine, as well as with the SSRI fluoxetine. Reboxetine is clearly effective in both the short and the long term compared with placebo. Against comparator antidepressants, reboxetine is at least as effective in the treatment of patients with major depressive disorder in the adult and the elderly population and offers a significant advantage over imipramine in the treatment of melancholic patients. In severely depressed patients, reboxetine was significantly more effective than fluoxetine. Reboxetine also offers significant advantages over fluoxetine in terms of social functioning and has a significantly improved adverse event profile compared with TCAs. In comparison with fluoxetine, reboxetine has a different adverse event profile, but shows advantages in terms of agitation/nervousness/anxiety and gastrointestinal events. Reboxetine is not cardiotoxic, and it is not associated with an increased risk of seizures or of orthostatic hypotension. Overall, reboxetine offers a significant safety advantage over TCAs in the treatment of the depressed population and in subsets of the depressed population in an efficacy comparison with the SSRI fluoxetine.

                    Reboxetine  research / abstracts

   1.  Reboxetine  role in antidepressant therapy
  2.  Reboxetine  efficacy and tolerability
  3.  Reboxetine  clinical pharmacologic profile
  4.  Reboxetine  Inhibiting noradrenaline and serotonin reuptake 
  5.  Reboxetine  and depression in the elderly
  6.  Reboxetine  with severe major depressive disorder
  7.  Reboxetine  clinical efficacy in major depression
  8.  Reboxetine  tolerability and safety for major depression
  9.  Reboxetine  comparison with fluoxetine
 10. Reboxetine  versus fluoxetine, impact on social functioning
 11. Reboxetine  versus fluoxetine, differential effects
 12. Reboxetine  prevents relapse in  major depression
 13. Reboxetine  efficacy compared with imipramine
 14. Noradrenaline reuptake inhibition
 15. Antidepressants  noradrenergic versus serotonergic
 16. Reboxetine  in the treatment of bulimia
 17. Reboxetine  hemodynamic effects in healthy males
 18. Reboxetine  effects of antidepressant therapy
 19. Reboxetine  place in antidepressant therapy
 20. Reboxetine  stimulant effects in patients with narcolepsy
 21. Reboxetine  selective noradrenaline reuptake inhibitor (NARI)

       Reboxetine  manufacturer's product insert

 

Hit Counter